News
Nyxoah to Release Q1 2024 Financial Results on May 14, 2024
Nyxoah
Nyxoah will release financial results for the first quarter of 2024 on May 14, 2024
Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA), today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 14, 2024, after market close. The company’s management will hold a conference call to discuss the financial results that day, starting at 10:30 pm CET / 4:30 pm ET.
A webcast of the conference call will be accessible on the Investor Relations page of the Nyxoah website or through this link: Nyxoah Q1 2024 Earnings Conference Call Webcast. For those who do not intend to ask questions to management, the Company recommends listening via webcast.
If you plan to ask a question, please use the following link: Nyxoah Q1 2024 Earnings Call. After registration, an email will be sent including dial-in details and a unique conference call access code required to participate in the live conference call. To ensure you are connected before the call begins, the Company suggests registering at least 10 minutes before the call begins.
The archived webcast will be available for replay shortly after the conference call ends.
About Nyxoah
Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA). Nyxoah’s flagship solution is the Genio® system, a patient-centered, lead-free, battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep-disordered breathing that is associated with increased risk of mortality and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel empowered to live their lives to the fullest.
For more information please visit http://www.nyxoah.com/.
Careful – CE marked since 2019. Research device in the United States. Limited by US federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations of the Company or, as appropriate, the Company’s directors or managers with respect to the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s objectives regarding the development, regulatory pathway and potential use of the Genio® system; the usefulness of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s operating results, financial situation, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors may adversely affect the outcome and financial effects of the plans and events described herein. In addition, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed at Securities and Exchange Commission. and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multiplicity of factors, including but not limited to changes in demand, competition and technology, may cause actual events, performance or results to differ significantly from any anticipated developments. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. Furthermore, even if actual results or developments are consistent with the forward-looking statements contained in this press release, such results or developments may not be indicative of results or developments in future periods. No representation or warranty is made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances under which these forward-looking statements are based unless specifically required by law or regulation. Neither the Company, nor its consultants or representatives, nor any of its subsidiary companies or officers or employees of any person warrant that the assumptions underlying such forward-looking statements are free from errors, nor accept any responsibility for the future accuracy of the forward-looking statements. statements contained in this press release or the actual occurrence of anticipated developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
The story continues
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com
Attachment
